ArticleJAAD international2026

Postmarketing safety of bimekizumab for hidradenitis suppurativa: An early pharmacovigilance analysis using the United States Food and Drug Administration Adverse Event Reporting System.

Simona A Alomary et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.